EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial

Stijn Franssen iD, Merve Rousian iD, Wills F Filipe, Florian E Buisman, Britte H E A Ten Haaft iD, Rutger-Jan Swijnenburg, Bianca Mostert iD, Nadia Haj Mohammad iD, Jeroen Hagendoorn, Michael Doukas iD, Heinz-Josef Klümpen, Marjolein Y V Homs und 1 weitere

Journal of Clinical Oncology · 20.02.2026 · 44 (6) · 455-465

DOI: 10.1200/jco-25-00923 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2026. Verfasst von Stijn Franssen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The 3-year overall survival (OS) for advanced intrahepatic cholangiocarcinoma (iCCA) confined to the liver after systemic chemotherapy with gemcitabine-cisplatin (gem-cis) is only 3%. Hepatic arterial infusion pump (HAIP) chemotherapy with floxuridine aims to control the liver disease and improve survival. The aim of this study was to assess the effectiveness of HAIP chemotherapy with floxuridine and concurrent systemic gem-cis in patients with unresectable liver-confined iCCA in the Netherlands. METHODS We performed a nonrandomized multicenter phase II trial. Treatment-naïve patients and patients previously treated with systemic therapy were eligible. Up to six cycles of HAIP floxuridine and eight cycles of concurrent systemic gem-cis were administered. The primary endpoint was 1-year OS compared with a historical cohort. RESULTS From January 2020 to September 2022, 50 patients had a pump placed. Two patients (4%) did not start HAIP floxuridine; one patient died due to COVID-19, and one patient had a hepatic arterial dissection. The remaining 48 patients (96%) started HAIP chemotherapy, combined with systemic gem-cis in the 37 patients (74%) who had not received gem-cis previously. Twenty-two patients (44%) achieved a partial response and 42 patients (84%) disease control at 6 months. Five patients (10%) converted to resection, of whom one had a complete pathologic response. The median OS was 22.3 months (95% CI, 19.7 to 35.9 months). The 1-year OS of 80.0% (95% CI, 69.6% to 91.9%) was superior to the historical control of 47% ( P < .001). The 3-year OS was 31.5% (95% CI, 20.4% to 48.6%). CONCLUSION Combining HAIP chemotherapy with floxuridine and systemic gem-cis in patients with unresectable liver-confined iCCA had a 1- and 3-year OS superior to gem-cis alone in historical cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedFloxuridineInfusions, Intra-ArterialHepatic ArteryGemcitabineCisplatinDeoxycytidineAdult

Substanzen

FloxuridineGemcitabineCisplatinDeoxycytidine

Autor:innen und Institutionen

  • Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Department of Surgery, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Department of Medical Oncology, UMC Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Surgery, UMC Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

ORCID-Profile: Stijn Franssen, Merve Rousian, Britte H E A Ten Haaft, Bianca Mostert, Nadia Haj Mohammad, Michael Doukas, Bas Groot Koerkamp

Zitieren

APA

Franssen, S., Rousian, M., Filipe, W. F., Buisman, F. E., Ten Haaft, B. H. E. A., Swijnenburg, R. J., Mostert, B., Haj Mohammad, N., Hagendoorn, J., Doukas, M., Klümpen, H. J., Homs, M. Y. V., & Groot Koerkamp, B. (2026). Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial. Journal of Clinical Oncology, 44(6), 455-465. https://doi.org/10.1200/jco-25-00923

Vancouver

Franssen S, Rousian M, Filipe WF, Buisman FE, Ten Haaft BHEA, Swijnenburg RJ, et al. Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial. Journal of Clinical Oncology. 2026;44(6):455-465. doi:10.1200/jco-25-00923

BibTeX
@article{Franssen2026,
  author = {Franssen, Stijn and Rousian, Merve and Filipe, Wills F and Buisman, Florian E and Ten Haaft, Britte H E A and Swijnenburg, Rutger-Jan and Mostert, Bianca and Haj Mohammad, Nadia and Hagendoorn, Jeroen and Doukas, Michael and Klümpen, Heinz-Josef and Homs, Marjolein Y V and Groot Koerkamp, Bas},
  title = {Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {6},
  pages = {455--465},
  doi = {10.1200/jco-25-00923}
}
Kostenlos starten →